COMPANY

CytoSorbents

Profile checked Oct 10, 2026

Keywords: Surgical Hemorrhage Hemorrhage Postoperative Surgical Blood Loss Postoperative Blood Loss Rhabdomyolysis Elective Cardiac Surgery Septic Shock Acute Respiratory Distress Syndrome Trauma Cardiogenic Shock Pancreatitis Acute on Chronic Liver Failure Acute Liver Failure Burns Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome Extracorporeal Life Support Postoperative Endocarditis Hemophagocytic Lymphohistiocytoses Infectious Disease Postoperative Vasoplegic Syndrome Drug Overdose Sepsis COVID-19 Emergent Cardiothoracic Surgery Bleeding Drug Removal CytoSorb DrugSorb-ATR system

9Trials (company is sponsor)7NIH grants

Timeline

Jun 22, 2022 Trial start —: CytOSorb TreatMent Of Critically Ill PatientS Registry source ↗
Dec 27, 2021 Trial start Not phased (device or behavioral study): Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D) source ↗
Sep 30, 2021 Trial start —: Safe and Timely Antithrombotic Removal (STAR) Registry source ↗
Aug 31, 2021 Trial start Not phased (device or behavioral study): Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) source ↗
Aug 28, 2020 Trial start —: Registry of CytoSorb Therapy in COVID-19 ICU Patients source ↗
Oct 29, 2019 Trial start Not phased (device or behavioral study): Ticagrelor CytoSorb Hemoadsorption source ↗
Apr 19, 2018 Trial start Not phased (device or behavioral study): CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery source ↗
2015-11 Trial start Not phased (device or behavioral study): CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery source ↗
2014-03 Trial start Phase 2: Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis source ↗

Upcoming milestones

2032-06 (ESTIMATED) · · CytOSorb TreatMent Of Critically Ill PatientS Registry · NCT05146336

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT05146336	CytOSorb TreatMent Of Critically Ill PatientS Registry	Not listed	Recruiting	Jun 22, 2022	2032-06 (estimated)
NCT05077124	Safe and Timely Antithrombotic Removal (STAR) Registry	Not listed	Recruiting	Sep 30, 2021	Sep 30, 2025 (estimated)
NCT05093504	Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)	Not phased (device or behavioral study)	Terminated	Dec 27, 2021	Jan 29, 2024 (actual)
NCT04976530	Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)	Not phased (device or behavioral study)	Completed	Aug 31, 2021	Aug 7, 2023 (actual)
NCT03384875	CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery	Not phased (device or behavioral study)	Terminated	Apr 19, 2018	Jan 18, 2022 (actual)
NCT04391920	Registry of CytoSorb Therapy in COVID-19 ICU Patients	Not listed	Completed	Aug 28, 2020	Jan 20, 2022 (actual)
NCT02111018	Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis	Phase 2	Withdrawn	2014-03	2016-06 (estimated)
NCT04131959	Ticagrelor CytoSorb Hemoadsorption	Not phased (device or behavioral study)	Terminated	Oct 29, 2019	May 4, 2021 (actual)
NCT02566525	CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery	Not phased (device or behavioral study)	Completed	2015-11	2016-10 (actual)

NIH awards 7

Annual award amounts. Total $4.2M.

Mar 3, 2023 NIH award 3R43GM144973-01S1 FY2023: $6,500 awarded for that fiscal year; activity R43 (SBIR); PI CHAN, PHILLIP; recipient as written: CYTOSORBENTS, INC., Princeton, NJ. Novel Extracorporeal Therapy for the Reversal o source ↗
Aug 29, 2022 NIH award 1R43GM144973-01 FY2022: $281,835 awarded for that fiscal year; activity R43 (SBIR); PI CHAN, PHILLIP; recipient as written: CYTOSORBENTS, INC., Princeton, NJ. Novel Extracorporeal Therapy for the Reversal o source ↗
Aug 10, 2020 NIH award 5R44HL141928-05 FY2020: $991,940 awarded for that fiscal year; activity R44 (SBIR); PI CHAN, PHILLIP; recipient as written: CYTOSORBENTS, INC., Princeton, NJ. pRBC Contaminant Removal with Hemocompatible Po source ↗
Sep 23, 2019 NIH award 5R44HL141928-04 FY2019: $983,050 awarded for that fiscal year; activity R44 (SBIR); PI CHAN, PHILLIP; recipient as written: CYTOSORBENTS, INC., Princeton, NJ. pRBC Contaminant Removal with Hemocompatible Po source ↗
Aug 16, 2018 NIH award 2R44HL141928-03 FY2018: $995,984 awarded for that fiscal year; activity R44 (SBIR); PI CHAN, PHILLIP; recipient as written: CYTOSORBENTS, INC., Princeton, NJ. pRBC Contaminant Removal with Hemocompatible Po source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 268201600006C-0-0-1 FY2016: $774,516 awarded for that fiscal year; activity N44 (OTHER_NIH); PI CHAN, PHILLIP; recipient as written: CYTOSORBENTS, INC., Princeton, NJ. IGF::OT::IGF To source ↗
2013 NIH contract (government contract; not a grant and not an investment round) 268201300044C-0-0-1 FY2013: $203,351 awarded for that fiscal year; activity N43 (OTHER_NIH); PI CHAN, PHILLIP; recipient as written: CYTOSORBENTS, INC., Princeton, NJ. DEVELOP A HEMOCO source ↗